Median Technologies inks dev deal with Medidata for cloud-based imaging tech

Median Technologies (EPA:ALMDT) and Medidata said today they inked a collaborative deal looking to leverage their capabilities to streamline the growth and use of medical imaging in cancer clinical trials. Through the deal, Median Technologies will use Medidata’s Clinical Cloud to accelerate oncology medicine development, the companies said. Median will also use Medidata’s Medical Imaging system to transition its existing legacy imaging study management systems to a single digital environment, the companies said. “Our collaboration with Medidata will not only ease the management of images during clinical drug trials—it will enhance our analytical rigor, enabling our teams to extract high-quality imaging biomarkers for better study and patient outcomes. Medidata’s imaging technology provides us with complementary capabilities to fulfill the unique R&D needs of our growing customer-base in Europe, Asia and the US. We’re dedicated to helping biopharmaceutical companies make more informed decisions to quickly bring new cancer therapies to market, and are thrilled to partner with Medidata to aid in those efforts,” Median Tech COO Jeanne Hecht said in a press release. “We are excited about our collaboration with Median, an organization that is setting the gold standard for diagnosing disease, developing new therapies and treating patients through the use of medical images. Medidata considers the entire image management process, t...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Clinical Trials Imaging Median Technologies Medidata Solutions Source Type: news

Related Links:

Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The host immune system plays a pivotal role in the emergence of tumor cells that are refractory to multiple clinical interventions including immunotherapy, chemotherapy, and radiotherapy. Here, we examined the molecular mechanisms by which the immune system triggers cross-resistance to these interventions. By examining the biological changes in murine and tumor cells subjected to sequential rounds of in vitro or in vivo immune selection via cognate cytotoxic T lymphocytes, we found that multimodality resistance arises through a core metabolic reprogramming pathway instigated by epigenetic loss of the ATP synthase subunit A...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
The immunologic landscape of tumors has been continuously unveiled, providing a new look at the interactions between cancer cells and the immune system. Emerging tumor cells are constantly eliminated by the immune system, but some cells establish a long-term equilibrium phase leading to tumor immunoediting and, eventually, evasion. During this process, tumor cells tend to acquire more mutations. Bearing a high mutation burden leads to a greater number of neoantigens with the potential to initiate an immune response. Although many tumors evoke an immune response, tumor clearance by the immune system does not occur due to a ...
Source: Clinics - Category: General Medicine Source Type: research
ConclusionsIn this review, we will present current and advanced therapeutic strategies for RC to help cancer survivors deal with long-term bladder health issues.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
The objective of this study was to evaluate the frequency of GLS reduction in patients with active cancer and its correlation to other echocardiographic parameters.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Authors: Ding Y, Zhou J, Wang S, Li Y, Mi Y, Gao S, Xu Y, Chen Y, Yan J Abstract Neuropilin-1 (NRP-1) is involved in a range of physiological and pathological processes, including neuronal cell guidance, cardiovascular development, immunity, angiogenesis and the pathogenesis of cancer. Targeting of NRP-1 is considered to be a potential cancer therapy and a number of approaches have been investigated, including the use of small interfering RNA, peptides, soluble NRP antagonists and monoclonal antibodies. The present study used a novel anti-neuropilin-1 monoclonal antibody (anti-NRP-1 mAb) to investigate its potentia...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
We present in vitro evidence that HDACi can enhance the radiosensitivity of human thyroid cancer cells.
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
In this study, we compared the long-term side effects of proton radiation to equivalent doses of X-rays in the initiation and progression of premalignant lesions in a lung cancer susceptible mouse model (K-rasLA1). We show proton irradiation causes more complex DNA damage that is not completely repaired resulting in increased oxidative stress in the lungs both acutely and persistently. We further observed K-rasLA1 mice irradiated with protons had an increased number and size of initiated and premalignant lesions and adenomas that were often infiltrated with inflammatory cells. Proton irradiated mice had a lower median surv...
Source: Life Sciences in Space Research - Category: Biology Source Type: research
This article discusses the pathophysiology and molecular mechanisms that contribute to cancer therapeutics-related cardiac dysfunction and presents an napproach to the evaluation and treatment of these patients.
Source: Heart Failure Clinics - Category: Cardiology Authors: Source Type: research
CONCLUSION: This approach merging qualitative and quantitative data suggests that mMCC patients report a better experience with avelumab than with chemotherapy. PMID: 30107762 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Environmental Health | Study